Form 4: ClearPoint Neuro CFO Danilo D'Alessandro Reports Stock Transactions
SEC Form 4 Filing
ClearPoint Neuro's CFO, Danilo D'Alessandro, reports the acquisition and disposal of common stock and restricted stock units.
Summary
- On March 11, 2025, Danilo D'Alessandro, CFO of ClearPoint Neuro, Inc., reported transactions involving ClearPoint Neuro's common stock and restricted stock units.
- D'Alessandro acquired 4,146 shares of common stock upon the settlement of restricted stock units.
- Simultaneously, D'Alessandro disposed of 2,106 shares to satisfy tax withholding obligations related to the vesting of the restricted stock units at a price of $12.7.
- Following these transactions, D'Alessandro directly owns 62,717 shares of ClearPoint Neuro common stock and 4,145 restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral regulatory filing detailing stock transactions by an insider. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC when a company insider, like the CFO, transacts in the company's stock. It provides transparency to the market regarding the trading activities of key personnel.
Stakeholder Impact
- The transactions have a minimal impact on shareholders as they represent routine insider activity related to executive compensation.
Key Dates
| Date | Description |
|---|---|
| 03/11/2025 | Date of earliest transaction: Acquisition of common stock and settlement of restricted stock units. |
| 03/13/2025 | Date of signature for the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.